- AnaptysBio's lead program, **rosnilimab**, completed a Phase IIb trial in rheumatoid arthritis (RA) in August 2025, showing **high impact and durable responses** with a **safe and tolerable profile**.  **[1370053_2145696_0]** 
- Initial data from rosnilimab's Phase IIb trial in ulcerative colitis (UC) is expected to read out in **Q4 2025** at three months, with a full strategic decision on the path forward anticipated after six-month data in **2026**.  **[1370053_2145696_0]** **[1370053_2145696_6]** 
- The company is well-capitalized with almost **$300 million** as of summer 2025 and expects a **$75 million milestone payment** from GSK due to dostarlimab (Jemperli) exceeding **$1 billion** in revenue in 2025.  **[1370053_2145696_0]** 
- AnaptysBio's second program, **ANB033**, a CD122 receptor antagonist, is nearing initiation of its initial Phase IB indication in celiac disease, with an investor relations event planned for **Q4 2025** to discuss the program.  **[1370053_2145696_0]** **[1370053_2145696_7]** 
- AnaptysBio addressed concerns regarding competitor Eli Lilly's PD-1 agonist, parasolumab, which showed malignancies in its Phase IIb study, asserting that rosnilimab is a **different drug** and its mechanism is **not linked to these safety concerns**, citing its own clean safety profile across hundreds of patients.  **[1370053_2145696_0]** **[1370053_2145696_1]** **[1370053_2145696_2]**

AnaptysBio Provides Updates on Rosnilimab Trials, Pipeline, and Financial Position

- AnaptysBio's lead program, rosnilimab, showed **remission rates surpassing best-in-class medicines** in a Phase IIb arthritis study and is expected to release initial data from its ulcerative colitis trial in **Q4 2025**.  **[1370053_tx_380776_0]** 
- The company's second program, ANB033, a CD122 antagonist, will have its initial Phase Ib indication in **celiac disease**, a market with **over 2 million patients in the U.S.** and no commercial drugs.  **[1370053_tx_380776_0]** **[1370053_tx_380776_7]** 
- AnaptysBio is **well-financed through year-end 2027** and holds significant royalty streams from GSK's Jemperli, with **royalties reaching up to 25%** and GSK guiding to **$2.5 billion in peak sales** for Jemperli monotherapy.  **[1370053_tx_380776_0]** **[1370053_tx_380776_7]**

ANAPTYSBIO (ANAB)